Global Expansion with Indian Medical Device Approval: What Works, Where It Works, and How to Use It Strategically

For Indian MedTech companies, global expansion almost always begins with the same question:

“Which countries can we enter using Indian CDSCO approval alone?”

It is a reasonable question. It is also one that often leads to expensive missteps when answered superficially. Over the past months, we conducted a region-by-region review of global medical device regulations to answer this question with precision. The result is not a list of “easy countries,” but a clear strategic map of where Indian regulatory approval genuinely enables market entry, where it works conditionally, and where it does not work at all. The detailed country-level tables are attached separately. This post focuses on what the data actually tells us and how Indian MedTech leaders should act on it.

THE EXACT QUESTION WE ANSWERED

“Can a medical device be registered in a country using only Indian regulatory approval, meaning a CDSCO Manufacturing Licence and or a CDSCO Free Sale Certificate, without requiring CE, US FDA, UKCA, TGA, PMDA, or any other reference-market approval?”

This is an assessment of regulatory eligibility, not speed, simplicity, distributor friendliness, or commercial success.

HOW HAVE WE SEGREGATED THIS DATA?

• Each country was evaluated by risk class, harmonized globally as: Class A/I, Class B/II, Class C/III, and Class D/IV (where applicable)

• Each outcome falls into one of four categories:

  • Yes – Indian approval alone is sufficient

  • Yes* – Indian approval is accepted conditionally

  • No – A foreign reference approval is mandatory

  • N/A – That risk class does not exist in the country’s framework

Nothing beyond this is implied.

GLOBAL REALITY, QUANTIFIED

Instead of anecdotal claims, the tables reveal a clear numerical pattern. Below is a summary of how countries fall across Yes, Yes*, No, and N/A by region and by risk class*.

Kindly view the tables below in the Light Mode:

Summary Table: Asia (49 countries)

Summary Table: Europe (EU consolidated + non-EU Europe, 28 entries)

Summary Table: North America (Including Central America and the Caribbean, 23 countries)

Summary Table: South America (12 countries)

Summary Table: Africa (54 countries)

Summary Table: Oceania and Rest of World (14 countries)

REGION-WISE ANALYSIS:

1. Indian Approval Is an Entry Enabler, not a Scale Enabler: Out of 180 countries globally, only 11 clearly accept Indian approval outright, 86 accept it conditionally, and 83 require reference-market approvals regardless. This means Indian approval is powerful for early entry and validation, but insufficient for long-term global scale.

2. Asia and Africa Are Where Indian Approval Has Real Leverage: Asia and Africa together account for the largest concentration of Yes and Yes* outcomes. These regions offer Indian MedTech companies the ability to: enter markets earlier, generate first export revenues, build distributor relationships, and de-risk later CE or FDA investments. This is where Indian approval delivers the highest strategic ROI.

3. Europe Is a Hard Stop: Europe, including the EU, UK, and non-EU Europe, shows zero acceptance across all classes. There are no practical exceptions. Any strategy that treats Europe as an India-first market is structurally flawed. There are no abridged/reliance pathway benefits using the Indian Approval alone.

4. Conditional Acceptance Is Not a Weak Signal: The dominance of Yes* outcomes is not a red flag. It reflects how regulators manage risk. Conditional acceptance still allows legal market entry, product registration, and revenue generation. The mistake companies make is treating conditional markets as permanent foundations rather than steppingstones.

WHAT THIS MEANS STRATEGICALLY FOR INDIAN MEDTECH COMPANIES

• If You Manufacture Class A or Low-Risk Devices: Indian CDSCO approval is a real strategic lever. It can be used to enter multiple markets quickly, validate international demand, generate early export revenue, and build distributor relationships. When used deliberately, it can fund and de-risk later reference-market approvals.

• If You Manufacture Class B Devices: Indian approval works best as a bridge strategy, not a destination.
  It supports learning and early traction, but cannot replace CE or FDA in the medium term.

• If You Manufacture Class C or Class D Devices: The data is unequivocal. Indian approval alone is not a viable global strategy. Reference-market approvals should be planned early and budgeted explicitly.

THE CRITERIA USED (BRIEF AND TRANSPARENT)

• Only the CDSCO Manufacturing Licence and the CDSCO Free Sale Certificate were considered

• “Yes” means no foreign approval required

• “Yes*” means conditional acceptance without mandatory foreign approval

• “No” means that at least one reference-market approval is required

• Emergency waivers and assumed MRAs were excluded

• Timeframe reflects current practice from 2024 to 2026

FINAL THOUGHTS?

Indian CDSCO approval is neither underrated nor overrated. It is misused. When applied strategically, it enables smart sequencing, faster learning, and capital-efficient expansion. When misunderstood, it creates false confidence and regulatory dead ends. The attached tables are meant to inform decisions.

If you are an Indian MedTech company planning to go global, the question is no longer whether Indian approval is “enough.” The real question is where, for which devices, and for how long. That is where strategy begins. The right regulatory sequence often determines whether global expansion becomes a growth story or an expensive detour.

If you are an Indian MedTech company planning international growth and want help translating this regulatory reality into a market entry or expansion strategy, or if you are looking for the analysis at the country-level, feel free to reach out.